Arcadia Biosciences, Inc.
RKDA · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | -0.00 | 0.00 | 0.00 |
| FCF Yield | -34.50% | -39.14% | -27.36% | -47.06% |
| EV / EBITDA | -0.76 | -0.76 | -1.77 | -0.08 |
| Quality | ||||
| ROIC | -8.41% | -11.30% | -20.27% | -18.10% |
| Gross Margin | 43.37% | 43.17% | 31.99% | 32.86% |
| Cash Conversion Ratio | -0.30 | 0.46 | -0.61 | 0.54 |
| Growth | ||||
| Revenue 3-Year CAGR | 2.33% | 1.98% | -11.78% | -19.43% |
| Free Cash Flow Growth | -28.02% | 28.11% | -26.08% | 28.75% |
| Safety | ||||
| Net Debt / EBITDA | 0.23 | 2.60 | 1.81 | 2.05 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.55 | 0.53 | 0.91 | 1.24 |
| Cash Conversion Cycle | 70.65 | 187.93 | 249.02 | 83.89 |